Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Viral Vector Manufacturing Market Growth in 2025?

The market size for viral vector manufacturing has seen a significant increase over the past few years. Anticipated growth is from $6.93 billion in 2024 to an estimated $8.33 billion in 2025, reflecting a compound annual growth rate (CAGR) of 20.1%. This considerable rise during the historic period can be connected to the development in gene therapy pipelines, clinical achievements and endorsements, escalated investment in biopharmaceuticals, and a heightened occurrence of genetic diseases.

What Is the Forecast for the Viral Vector Manufacturing Market Size Through 2029?

In the coming years, it is anticipated that the market size for viral vector manufacturing will experience substantial expansion. The market is projected to reach $17.68 billion by the year 2029, growing at a compound annual growth rate (CAGR) of 20.7%. This growth during the projected period can be associated with the growing use in oncology, global collaborative efforts in gene therapy research, viral vector utilization in vaccine development, ongoing clinical trial proceedings and commercialization. Key trends within the projected period range from technology advancements in vector production, the emergence of next-gen vectors, compliance and standardization of regulations, collaborative alliances and partnerships, and global augmentation of production facilities.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12398&type=smp

What are the Key Market Players in Viral Vector Manufacturing Market and How They’re Evolving?

Major companies operating in the viral vector manufacturing market include Sanofi S.A., Thermo Fisher Scientific Inc., Merck Group, FUJIFILM Holdings Corporation, Lonza Group, Catalent Inc., Sartorius AG, Charles River Laboratories International Inc., AGC Biologics, Ultragenyx Pharmaceutical Inc., Novasep Holding SAS, Aldevron LLC, Oxford Biomedica plc, LakePharma Inc., Voyager Therapeutics Inc., Mustang Bio Inc., Regenxbio Inc., VGXI Inc., BioNTech IMFS GmbH, FinVector Oy, Vigene Biosciences Inc., Univercells Technologies, Sirion-Biotech GmbH, Cevec Pharmaceuticals GmbH, Batavia Biosciences BV.

What Are the Primary Growth Drivers in the Viral Vector Manufacturing Market?

The rise in cancer and infectious disease incidences are anticipated to fuel the advancement of the viral vector manufacturing market. An infectious disease is defined as a condition induced by a virus or its harmful secondary product, which can be transmitted to a vulnerable host through interaction with an affected person, animal, or object. Cancer, on the other hand, encompasses a wide spectrum of diseases that occur when abnormal cells uncontrollably multiply, crossing their typical boundaries to invade adjacent organs, and metastasize to other organs. Through viral vectors, tumour antigens or proteins found on tumour cells are created to provoke the body’s anticancer immunological response. Viral vectors have been utilized as vaccines against a variety of infectious diseases encountered in pre-clinical and clinical trials. For example, the Australian Institute of Health and Welfare, a government agency based in Australia, reported in July 2024 that the number of cancer diagnosis in Australia had surged from 160,570 in 2022 to 164,694 in 2023, marking a significant increase over the year. This trend underscores the escalating cancer rates within the country. Furthermore, in August 2024, the UK Health Security Agency, an executive agency based in the UK, revealed 368 measles cases in England in 2023. This figure represents an almost sevenfold increase from the 53 cases documented in 2022, with 44% and 33% of the cases found in the West Midlands and London, respectively. Hence, the increased incidences of cancer and infectious diseases are propelling the growth of the viral vector manufacturing market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12398&type=smp

What Are the Leading Segments in the Global Viral Vector Manufacturing Industry?

The viral vector manufacturing market covered in this report is segmented –

1) By Type: Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, Other Types

2) By Disease: Cancer, Genetic Disorders, Infectious Diseases, Other Diseases

3) By Workflow: Upstream Processing, Downstream Processing

4) By Application: Gene And Cell Therapy Development, Vaccine Development, Biopharmaceutical And Pharmaceutical Discovery, Biomedical Research

5) By End-User: Research Organizations, Biotech And Pharmaceutical Companies, Others End Users

Subsegments:

1) By Adenoviral Vectors: Serotype 5, Serotype 2, Serotype 26

2) By Adeno-Associated Viral Vectors: AAV2, AAV5, AAV8, AAV9, Others

3) By Lentiviral Vectors: HIV-1-Based Lentiviral Vectors, SIV-Based Lentiviral Vectors, Others

4) By Retroviral Vectors: Moloney Murine Leukemia Virus (MoMLV), Gammaretroviral Vectors, Others

5) By Other Types: Sendai Viral Vectors, Vesicular Stomatitis Virus (VSV)-Based Vectors, Measles Virus Vectors, Others

What Are the Key Market Trends in the Viral Vector Manufacturing Industry?

A significant development in the viral vector manufacturing market is product innovation. Established corporations in the sector are employing this strategy to maintain their market position. Merck KGaA, a German science and technology firm, exemplifies this trend. In August 2022, the company introduced its innovative VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform. This makes them one of the first Contract Development and Manufacturing Organizations and technology developers to provide an all-inclusive package for viral vector manufacturing. These include AAV, Lentiviral, CDMO, CTO, and process development services. This innovative platform enables biopharmaceutical companies to minimize the cost and duration of process development while speeding up clinical production time.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

What Is the Regional Outlook for the Viral Vector Manufacturing Market?

North America was the largest region in the viral vector manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12398

This Report Delivers Insight On:

1. How big is the viral vector manufacturing market, and how is it changing globally?

2. Who are the major companies in the viral vector manufacturing market, and how are they performing?

3. What are the key opportunities and risks in the viral vector manufacturing market right now?

4. Which products or customer segments are growing the most in the viral vector manufacturing market?

5. What factors are helping or slowing down the growth of the viral vector manufacturing market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model